CD307C抗体,Mouse Monoclonal CD307C Antibody
  • CD307C抗体,Mouse Monoclonal CD307C Antibody
  • CD307C抗体,Mouse Monoclonal CD307C Antibody
  • CD307C抗体,Mouse Monoclonal CD307C Antibody

CD307C抗体—艾普蒂

价格 询价
包装 20μl 50μl 100μl
最小起订量 1μl
发货地 上海
更新日期 2025-05-15
QQ交谈 微信洽谈

产品详情

中文名称:CD307C抗体英文名称:Mouse Monoclonal CD307C Antibody
品牌: 艾普蒂产地: 武汉
保存条件: Stored at -20°C for 1179 year. Avoid repeated freeze / thaw cycles.产品类别: 抗体
重组: 应用: WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性: Human,Mouse,Rat 宿主: Mouse
偶联物: 靶点: CD307C
2025-05-15 CD307C抗体 Mouse Monoclonal CD307C Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武汉 Stored at -20°C for 1179 year. Avoid repeated freeze / thaw cycles. 抗体

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC咨询技术 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM1/200 - 1/400 Human,Mouse,Rat
Elisa1/10000 Human,Mouse,Rat
   

产品详情

AliasesFCRL3; FCRH3; IFGP3; IRTA3; SPAP2
Entrez GeneID115352
clone4D7B9
WB Predicted band size80.9kDa
Host/IsotypeMouse IgG1
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenPurified recombinant fragment of human CD307C (AA: extra 18-153) expressed in E. Coli.
FormulationPurified antibody in PBS with 0.05% sodium azide

+ +

  •  

     

       Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    


  •  

     

       Flow cytometric analysis of HL-60 cells using CD307C mouse mAb (green) and negative control (red).    


           

参考文献

以下是关于CD307C(FCRL3)抗体的假设参考文献示例,供参考。实际文献需通过学术数据库(如PubMed、Google Scholar)检索确认:

---

1. **"Development of a Monoclonal Antibody Targeting Human CD307c (FCRL3) for B Cell Analysis"**

*Authors: Zhang Y, Wang L, et al.*

**摘要**: 描述了抗CD307C单克隆抗体的开发与表征,验证其在流式细胞术和免疫荧光中对B细胞亚群的特异性检测,揭示FCRL3在调节性B细胞中的表达模式。

2. **"FCRL3 Modulates B Cell Receptor Signaling via Antibody-Mediated Blockade in Autoimmunity"**

*Authors: Müller S, Johnson R, et al.*

**摘要**: 通过抗CD307C抗体阻断实验,证明FCRL3抑制B细胞受体(BCR)信号传导,可能成为自身免疫性疾病(如类风湿性关节炎)的潜在治疗靶点。

3. **"CD307c Expression in Chronic Lymphocytic Leukemia: Prognostic Implications and Antibody-Based Detection"**

*Authors: Rossi G, Brown K, et al.*

**摘要**: 使用抗CD307C抗体分析慢性淋巴细胞白血病(CLL)患者的样本,发现其高表达与疾病进展相关,提示其作为预后生物标志物的潜力。

4. **"Structural and Functional Insights into FCRL3 Through Monoclonal Antibody Mapping"**

*Authors: Lee H, Smith T, et al.*

**摘要**: 结合X射线晶体学与抗CD307C抗体的表位定位,解析FCRL3的免疫调节结构域,为靶向药物设计提供依据。

---

**提示**:建议使用关键词“CD307c antibody”“FCRL3 monoclonal antibody”或“FCRL3 B cell function”在学术平台检索最新文献。部分真实研究可能聚焦于FCRL3的免疫调节功能及抗体工具的开发应用。

       

背景信息

CD307c antibody targets the CD307c antigen, also known as FCRL3 (Fc receptor-like 3), a member of the Fc receptor-like (FCRL) family expressed primarily on B lymphocytes. FCRL proteins share structural homology with classical Fc receptors but lack binding affinity for immunoglobulins. CD307c is characterized by extracellular immunoglobulin-like domains and cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) or activating motifs (ITAMs), enabling modulation of B-cell receptor (BCR) signaling. It plays dual roles in immune regulation, either dampening or enhancing B-cell activation depending on cellular context and ligand interactions.

Research highlights CD307c's association with autoimmune diseases and malignancies. Genetic polymorphisms in *FCRL3* are linked to increased susceptibility to rheumatoid arthritis, systemic lupus erythematosus (SLE), and autoimmune thyroid disorders, suggesting its role in immune tolerance. In B-cell cancers, CD307c is overexpressed in chronic lymphocytic leukemia (CLL) and certain lymphomas, positioning it as a potential diagnostic marker or therapeutic target.

CD307c antibodies are valuable tools for studying B-cell biology, dissecting FCRL3 signaling pathways, and exploring therapeutic applications. Neutralizing antibodies may suppress pathogenic B-cell activity in autoimmunity, while antibody-drug conjugates (ADCs) or bispecific antibodies are under investigation for targeting CD307c-positive malignancies. Ongoing studies aim to clarify its ligand interactions and tissue-specific functions, with implications for precision immunotherapy.

       
关键字: CD307C抗体;CD307C;CD307C Antibody;

公司简介

是一家科研、开发、生产和销售为一体的科技型企业,
成立日期 2024-07-02 (2年) 注册资本 20万人民币
员工人数 1-10人 年营业额 ¥ 100万以内
主营行业 抗体,蛋白组学,细胞生物学 经营模式 贸易,工厂,试剂,定制,服务
  • 上海切尔齐生物科技有限公司
VIP 1年
  • 公司成立:2年
  • 注册资本:20万人民币
  • 企业类型:有限责任公司(自然人投资或控股)
  • 主营产品:重组蛋白、抗体、生物试剂
  • 公司地址:青浦区
询盘

CD307C抗体—艾普蒂相关厂家报价

产品名称 价格   公司名称 报价日期
询价
上海华盈生物医药科技有限公司
2025-12-28
¥1338
VIP2年
普健生物(武汉)科技有限公司
2025-12-26
询价
广州市格瑞林生物科技有限公司
2025-12-25
内容声明:
以上所展示的信息由商家自行提供,内容的真实性、准确性和合法性由发布商家负责。 商家发布价格指该商品的参考价格,并非原价,该价格可能随着市场变化,或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格,请咨询商家,以实际成交价格为准。请意识到互联网交易中的风险是客观存在的
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 |投诉中心
Copyright © 2008 ChemicalBook 京ICP备07040585号  京公海网安备110108000080号  All rights reserved.